Operating income before deduction of amortization: Mind Medicine (MindMed) Inc. (MNMD)

Brandmark of MindMed (MNMD)

Mind Medicine develops psychedelic treatments for the therapy of mental pathologies. The EBITDA_Co trend reflects cash flow dynamics, where the parameter has stabilized at 0.00. The business model relies on third-party contractors for synthesis and testing, while project success remains tied to regulatory verdicts and the rate of capital expenditure.

Mind Medicine (MNMD) Operating profit EBITDA: for the period 11/23/2025 - 01/15/2026

Summary analytical data breakdowns for MindMed (MNMD)

- share price and consensus valuation forecast:
Quote Chart Mind Medicine Corp|MNMD - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization MindMed|MNMD - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Asset Value per Share MindMed|MNMD - Book Capitalization|Market Cap to Net Assets Ratio mindmed.co|MNMD - Company Total Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Mind Medicine|MNMD - Long-Term Debt to Equity|Current Liabilities to Capital Mind Medicine (MindMed) Inc.|MNMD - Company Debts|Debt to Book Value MindMed|MNMD - Company Long-Term Debts|Short-Term Debt Volume MindMed|Immediate Liquidity Ratio mindmed.co
- earnings and market multiples details:
MNMD - Net Profit|Net Profit Forecast Mind Medicine|MNMD - Price to Earnings Ratio|Future Price to Earnings Multiple mindmed.co|MNMD - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio MindMed|MNMD - Operating profit EBITDA|Net earnings per one share for the last twelve months MindMed|MNMD - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months mindmed.co|MNMD - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Mind Medicine
Analysis of all company metrics:MNMD - Mind Medicine Corp
Brand item of Mind Medicine

This indicator measures daily cash flow from operating activities, adjusted for non-cash charges, reflecting the real ability of Mind Medicine (MNMD) to generate cash. Analyzing EBITDA allows for an assessment of cost efficiency regarding the diversification of clinical trials for various molecules. The EBITDA trend reveals the cost of maintaining a broad drug pipeline. This helps investors correlate spending rates with the potential for patient reach. The stability of this metric confirms the resilience of the risk mitigation strategy.

Who Mind Medicine competes with

ALKS (Alkermes Corp) - Profit before deduction of interest, taxes, depreciation and amortization|AVDL - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization atai.life ATAI|GHRS (GH Research) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization COMPASS Pathways PLC (CMPS)|LBRX (LB Pharma) - Operating profit EBITDA|Operating profit before deduction of amortization Bright Minds Corp (DRUG)|Operating profit EBITDA VNDA|CYBN (cybin.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Profit before interest, taxes and amortization|CING - Profit before payment of interest, taxes and amortization|Silo Pharma Inc. (SILO) - Operating profit before deduction of amortization|CPHI: Operating profit EBITDA|CMND - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Psyence Biomedical|Operating profit before amortization SPRC (SciSparc Ltd.)|Operating profit EBITDA SEEL|virpaxpharma.com - Operating profit before amortization|Karuna Therapeutics - Operating profit before deduction of amortization